Strength in Numbers: EU Cross-Country Drug Pricing Coalitions Join Forces
Concerns Emerge Over Insufficient Data To Support Decision-Making
Two groups of smaller European countries have agreed to collaborate on tackling challenges relating to accessing expensive new medicines.
You may also be interested in...
The Dutch HTA institute is calling for hefty discounts of 50% and 75% for Novartis’s gene therapy and Vertex’s cystic fibrosis product.
Nine countries are joining forces on horizon scanning with the aim of improving their chances of securing lower prices for high-cost drugs.
If approved, new legislation would allow hospitals to apply for funding for ATMPs before marketing authorization.